MicroRNA-301a modulates doxorubicin resistance in osteosarcoma cells by targeting AMP-activated protein kinase alpha...

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• MicroRNAs (miRNAs) play roles in cancer drug resistance.
• MicroRNA-301a (miR-301a) is an oncogene in various cancers, but its role in osteosarcoma (OS) drug resistance is unclear.
• Doxorubicin is a common chemotherapy agent for osteosarcoma.

Purpose of the Study:

• To investigate the role of miR-301a in doxorubicin resistance in osteosarcoma (OS) cells.
• To identify the molecular mechanisms underlying miR-301a-mediated chemoresistance.
• To evaluate miR-301a as a potential biomarker and therapeutic target for chemoresistant OS.

Main Methods:

• Doxorubicin treatment of OS cells to assess time-dependent miR-301a expression.
• Overexpression and knockdown of miR-301a to study its effects on cell apoptosis and drug sensitivity.
• Luciferase reporter assay to confirm the direct targeting of AMPKα1 by miR-301a.
• Analysis of miR-301a and HMGCR expression in clinical samples of chemoresistant OS.

Main Results:

• Doxorubicin induced time-dependent upregulation of miR-301a in OS cells.
• miR-301a overexpression facilitated doxorubicin-induced HMGCR upregulation and AMPKα1 downregulation.
• Luciferase assay confirmed AMPKα1 as a direct target of miR-301a.
• miR-301a reduced doxorubicin-induced apoptosis, while anti-miR-301a enhanced it, indicating miR-301a confers chemoresistance.
• miR-301a and HMGCR were upregulated in chemotherapy-resistant OS tissues.

Conclusions:

• miR-301a contributes to doxorubicin resistance in osteosarcoma by targeting AMPKα1 and reducing apoptosis.
• Upregulation of miR-301a and HMGCR is associated with chemotherapy resistance in OS.
• miR-301a represents a potential biomarker for chemoresistant OS and a therapeutic target for overcoming drug resistance.